3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
5
Recruiting
2
Unknown
1
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
69
Head & Neck
43
Thoracic
12
Tumor-Agnostic
7
CNS
5
Gynecologic
4
Breast
3
Sarcoma
2
Other solid neoplasm
2
Genitourinary
2
Plasma cell
1
Myeloid
1
Lymphoid
1
Dermatologic
1
Conditions
Sarcoma
1
Neoplasm Metastasis
1
Melanoma
1
Interventions
pembrolizumab
58
Ipilimumab
53
Cyclophosphamide
53
Nivolumab
45
aldesleukin
35
Interleukin-2
26
fludarabine phosphate
22
fludarabine
21
Vemurafenib
20
Temozolomide
19
Radiotherapy
19
dabrafenib
15
trametinib
12
Radiosurgery
11
CTLA-4 Antigen
11
spartalizumab
10
Filgrastim
10
Dacarbazine
10
cobimetinib
9
binimetinib
9
atezolizumab
9
Biopsy
9
poly ICLC
8
Paclitaxel
8
Antilymphocyte Serum
8
encorafenib
7
avelumab
7
Rituximab
7
Introns
7
romidepsin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Cetuximab
×
Dermatologic
×
Clear all
NCT03009058
2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2
Terminated
2 enrolled
7 charts